{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:24:12Z","timestamp":1761578652492},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s11886-020-1262-1","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T19:03:02Z","timestamp":1580324582000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Beta-Blockers, Calcium Channel Blockers, and Mortality in Stable Coronary Artery Disease"],"prefix":"10.1007","volume":"22","author":[{"given":"Jose B.","family":"Cruz Rodriguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haider","family":"Alkhateeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,29]]},"reference":[{"issue":"24","key":"1262_CR1","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","volume":"64","author":"Ezra A. Amsterdam","year":"2014","unstructured":". Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34: 2949\u20133003. doi: https:\/\/doi.org\/10.1016\/j.jacc.2014.09.017","journal-title":"Journal of the American College of Cardiology"},{"key":"1262_CR2","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1016\/j.jacc.2012.07.013","volume":"126","author":"SD Fihn","year":"2012","unstructured":"Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF\/AHA\/ACP\/AATS\/ PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular (probably a typo)Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:e354\u2013471. https:\/\/doi.org\/10.1016\/j.jacc.2012.07.013.","journal-title":"Circulation"},{"issue":"11","key":"1262_CR3","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","volume":"297","author":"PG Steg","year":"2007","unstructured":"Steg PG, Bhatt DL, Wilson PW, D\u2019Agostino R Sr, Ohman EM, Rother J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297(11):1197\u2013206. https:\/\/doi.org\/10.1001\/jama.297.11.1197.","journal-title":"JAMA."},{"key":"1262_CR4","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1161\/CIRCOUTCOMES.114.001073","volume":"7","author":"S Bangalore","year":"2014","unstructured":"Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW, et al. Beta-blockers and cardiovascular events in patients with and without myocardial infarction: post-hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes. 2014;7:872\u201381. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.114.001073.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1262_CR5","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bmj.38695.605440.AE","volume":"332","author":"CA Daly","year":"2006","unstructured":"Daly CA, De Stavola B, Sendon JL, Tavazzi L, Boersma E, Clemens F, et al. Predicting prognosis in stable angina: results from the Euro heart survey of stable angina: prospective observational study. BMJ. 2006;332:262\u20137. https:\/\/doi.org\/10.1136\/bmj.38695.605440.AE.","journal-title":"BMJ"},{"key":"1262_CR6","volume-title":"Morbidity & Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases","author":"National Institutes of Health NH, Lung, and Blood Institute","year":"2012","unstructured":"National Institutes of Health NH, Lung, and Blood Institute. Morbidity & Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda: National Heart, Lung, and Blood Institute; 2012."},{"key":"1262_CR7","doi-asserted-by":"publisher","first-page":"i4801","DOI":"10.1136\/bmj.i4801","volume":"354","author":"E Puymirat","year":"2016","unstructured":"\u2022 Puymirat E, Riant E, Aissaoui N, et al. Beta blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ. 2016;354:i4801. https:\/\/doi.org\/10.1136\/bmj.i4801 After MI, early BB use was associated with reduced 30-day mortality and discontinuation one year was not associated with higher 5-year mortality.","journal-title":"BMJ"},{"issue":"4","key":"1262_CR8","doi-asserted-by":"publisher","first-page":"e004356","DOI":"10.1161\/CIRCOUTCOMES.117.004356","volume":"11","author":"A Neumann","year":"2018","unstructured":"\u2022 Neumann A, Maura G, Weill A, Alla F, Danchin N. Clinical events after discontinuation of \u03b2-blockers in patients without heart failure optimally treated after acute myocardial infarction: a cohort study on the French Healthcare Databases. Circ Cardiovasc Qual Outcomes. 2018;11(4):e004356. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.117.004356 Discontinuation of BB one year after MI showed increased risk of death due to ACS, although not significant for all-cause mortality.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1262_CR9","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1001\/jama.2012.12559","volume":"308","author":"S Bangalore","year":"2012","unstructured":"Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, et al. Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308:1340\u20139. https:\/\/doi.org\/10.1001\/jama.2012.12559.","journal-title":"JAMA"},{"key":"1262_CR10","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(04)16980-8","volume":"364","author":"PA Poole-Wilson","year":"2004","unstructured":"Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized controlled trial. Lancet. 2004;364:849\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(04)16980-8.","journal-title":"Lancet"},{"issue":"1","key":"1262_CR11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/oxfordjournals.eurheartj.a014668","volume":"17","author":"HJ Dargie","year":"1996","unstructured":"Dargie HJ, Ford I, Fox KM, TIBET Study Group. Total Ischaemic Burden European Trial (TIBET) Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J. 1996;17(1):104\u201312. https:\/\/doi.org\/10.1093\/oxfordjournals.eurheartj.a014668.","journal-title":"Eur Heart J"},{"key":"1262_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0002-9149(94)90721-8","volume":"73","author":"WA Wallace","year":"1994","unstructured":"Wallace WA, Wellington KL, Chess MA, Liang CS. Comparison of nifedipine gastrointestinal therapeutic system and atenolol on antianginal efficacies and exercise hemodynamic responses in stable angina pectoris. Am J Cardiol. 1994;73:23\u20138. https:\/\/doi.org\/10.1016\/0002-9149(94)90721-8.","journal-title":"Am J Cardiol"},{"key":"1262_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/0167-5273(94)02194-N","volume":"47","author":"LL van de Ven","year":"1995","unstructured":"van de Ven LL, Vermeulen A, Tans JG, Tans AC, Liem KL, Lageweg NC, et al. Which drug to choose for stable angina pectoris: a comparative study between bisoprolol and nitrates. Int J Cardiol. 1995;47:217\u201323. https:\/\/doi.org\/10.1016\/0167-5273(94)02194-N.","journal-title":"Int J Cardiol"},{"key":"1262_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0167-5273(93)90277-N","volume":"40","author":"R Steffensen","year":"1993","unstructured":"Steffensen R, Grande P, Pedersen F, Haunso S. Effects of atenolol and diltiazem on exercise tolerance and ambulatory ischaemia. Int J Cardiol. 1993;40:143\u201353. https:\/\/doi.org\/10.1016\/0167-5273(93)90277-N.","journal-title":"Int J Cardiol"},{"key":"1262_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/oxfordjournals.eurheartj.a014699","volume":"17","author":"KM Fox","year":"1996","unstructured":"Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ, The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Eur Heart J. 1996;17:96\u2013103. https:\/\/doi.org\/10.1093\/oxfordjournals.eurheartj.a014699.","journal-title":"Eur Heart J"},{"key":"1262_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0167-5273(96)02806-9","volume":"57","author":"RJ de Vries","year":"1996","unstructured":"de Vries RJ, van den Heuvel AF, Lok DJ, Claessens RJ, Bernink PJ, Pasteuning WH, et al. Nifedipine gastrointestinal therapeutic system versus atenolol in stable angina pectoris. The NetherlandsWorking Group on Cardiovascular Research (WCN). Int J Cardiol. 1996;57:143\u201350. https:\/\/doi.org\/10.1016\/S0167-5273(96)02806-9.","journal-title":"Int J Cardiol"},{"key":"1262_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/0735-1097(92)90499-D","volume":"19","author":"DT Kawanishi","year":"1992","unstructured":"Kawanishi DT, Reid CL, Morrison EC, Rahimtoola SH. Response of angina and ischemia to long-term treatment in patients with chronic stable angina: a doubleblind randomized individualized dosing trial of nifedipine, propranolol and their combination. J Am Coll Cardiol. 1992;19:409\u201317. https:\/\/doi.org\/10.1016\/0735-1097(92)90499-D.","journal-title":"J Am Coll Cardiol"},{"key":"1262_CR18","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/BF00877726","volume":"7","author":"TE Meyer","year":"1993","unstructured":"Meyer TE, Adnams C, Commerford P. Comparison of the efficacy of atenolol and its combination with slow-release nifedipine in chronic stable angina. Cardiovasc Drugs Ther. 1993;7:909\u201313. https:\/\/doi.org\/10.1007\/BF00877726.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1262_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/oxfordjournals.eurheartj.a014695","volume":"17","author":"N Rehnqvist","year":"1996","unstructured":"Rehnqvist N, Hjemdahl P, Billing E, Bjorkander I, Eriksson SV, Forslund L, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J. 1996;17:76\u201381. https:\/\/doi.org\/10.1093\/oxfordjournals.eurheartj.a014695.","journal-title":"Eur Heart J"},{"key":"1262_CR20","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","volume":"334","author":"M Packer","year":"1996","unstructured":"Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349\u201355. https:\/\/doi.org\/10.1056\/NEJM199605233342101.","journal-title":"N Engl J Med"},{"key":"1262_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"CIBIS-II Investigators and Committees","year":"1999","unstructured":"CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9\u201313. https:\/\/doi.org\/10.1016\/S0140-6736(98)11181-9.","journal-title":"Lancet"},{"key":"1262_CR22","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1001\/jama.1988.03410140100032","volume":"260","author":"S Yusuf","year":"1988","unstructured":"Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I Treatments following myocardial infarction. JAMA. 1988;260:2088\u201393. https:\/\/doi.org\/10.1001\/jama.1988.03410140100032.","journal-title":"JAMA"},{"key":"1262_CR23","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.jacc.2015.07.047","volume":"66","author":"JJ Goldberger","year":"2015","unstructured":"Goldberger JJ, Bonow RO, Cuffe M, Liu L, Rosenberg Y, Shah PK, et al. Effect of beta-blocker dose on survival after acute myocardial infarction. J Am Coll Cardiol. 2015;66:1431\u201341. https:\/\/doi.org\/10.1016\/j.jacc.2015.07.047.","journal-title":"J Am Coll Cardiol"},{"key":"1262_CR24","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","volume":"283","author":"A Hjalmarson","year":"2000","unstructured":"Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283:1295\u2013302. https:\/\/doi.org\/10.1001\/jama.283.10.1295.","journal-title":"JAMA"},{"key":"1262_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jacc.2014.04.042","volume":"64","author":"C Andersson","year":"2014","unstructured":"Andersson C, Shilane D, Go AS, Chang TI, Kazi D, Solomon MD, et al. Beta-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. J Am Coll Cardiol. 2014;64:247\u201352. https:\/\/doi.org\/10.1016\/j.jacc.2014.04.042.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"1262_CR26","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1093\/eurheartj\/ehy811","volume":"40","author":"E Sorbets","year":"2019","unstructured":"\u2022 Sorbets E, Steg PG, Young R, Danchin N, Greenlaw N, Ford I, et al. \u03b2-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. Eur Heart J. 2019;40(18):1399\u2013407. https:\/\/doi.org\/10.1093\/eurheartj\/ehy811 Large contemporary cohort of SCAD showing the outcomes associated with CCB and BB.","journal-title":"Eur Heart J"},{"key":"1262_CR27","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.amjmed.2012.01.014","volume":"125","author":"PW Wilson","year":"2012","unstructured":"Wilson PW, D\u2019Agostino R Sr, Bhatt DL, Eagle K, Pencina MJ, Smith SC, et al. REACH Registry. An international model to predict recurrent cardiovascular disease. Am J Med. 2012;125:695\u2013703.e1. https:\/\/doi.org\/10.1016\/j.amjmed.2012.01.014.","journal-title":"Am J Med"},{"issue":"3","key":"1262_CR28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.11909\/j.issn.1671-5411.2019.03.008","volume":"16","author":"AH Malik","year":"2019","unstructured":"\u2022 Malik AH, Shetty S, Kar K, El Accaoui R. Effect of \u03b2-blocker therapy in diabetic patients with stable coronary heart disease: a meta-analysis. J Geriat Cardiol. 2019;16(3):291\u20137. https:\/\/doi.org\/10.11909\/j.issn.1671-5411.2019.03.008 BB therapy in diabetic patients with SCHD appears to be linked to higher mortality.","journal-title":"J Geriat Cardiol"},{"issue":"16","key":"1262_CR29","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.jcin.2016.05.048","volume":"9","author":"AA Motivala","year":"2016","unstructured":"Motivala AA, Parikh V, Roe M, Dai D, Abbott JD, Prasad A, et al. Predictors, trends, and outcomes (among older patients\u2265 65 years of age) associated with beta-blocker use in patients with stable angina undergoing elective percutaneous coronary intervention: insights from the NCDR registry. J Am Coll Cardiol Intv. 2016;9(16):1639\u201348. https:\/\/doi.org\/10.1016\/j.jcin.2016.05.048.","journal-title":"J Am Coll Cardiol Intv"},{"issue":"17","key":"1262_CR30","doi-asserted-by":"publisher","first-page":"J9","DOI":"10.1016\/0002-9149(87)90207-4","volume":"59","author":"CA Visser","year":"1987","unstructured":"Visser CA, Koolen JJ, van Wezel H, Dunning AJ. Hemodynamics of nicardipine in coronary artery disease. Am J Cardiol. 1987;59(17):J9\u201312. https:\/\/doi.org\/10.1016\/0002-9149(87)90207-4.","journal-title":"Am J Cardiol"},{"issue":"4","key":"1262_CR31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0033-0620(96)80014-4","volume":"38","author":"LH Opie","year":"1996","unstructured":"Opie LH. Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use. Prog Cardiovasc Dis. 1996;38(4):273\u201390. https:\/\/doi.org\/10.1016\/S0033-0620(96)80014-4.","journal-title":"Prog Cardiovasc Dis"},{"key":"1262_CR32","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","volume":"290","author":"CJ Pepine","year":"2003","unstructured":"Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805\u201316. https:\/\/doi.org\/10.1001\/jama.290.21.2805.","journal-title":"JAMA"},{"key":"1262_CR33","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/01.psy.0000160468.69451.7f","volume":"67","author":"LD Ried","year":"2005","unstructured":"Ried LD, Tueth MJ, Handberg E, Kupfer S, Pepine CJ. A study of antihypertensive drugs and depressive symptoms (SADD-Sx) in patients treated with a calcium antagonis versus an atenolol hypertension treatment strategy in the International Verapamil SR-Trandolapril Study (INVEST). Psychosom Med. 2005;67:398\u2013406. https:\/\/doi.org\/10.1097\/01.psy.0000160468.69451.7f.","journal-title":"Psychosom Med"},{"key":"1262_CR34","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","volume":"292","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217\u201325. https:\/\/doi.org\/10.1001\/jama.292.18.2217.","journal-title":"JAMA"},{"key":"1262_CR35","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0002-9149(98)00904-7","volume":"83","author":"WH Frishman","year":"1999","unstructured":"Frishman WH, Glasser S, Stone P, Deedwania PC, Johnson M, Fakouhi TD. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol. 1999;83:507\u201314. https:\/\/doi.org\/10.1016\/S0002-9149(98)00904-7.","journal-title":"Am J Cardiol"},{"issue":"4","key":"1262_CR36","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.amjmed.2008.09.043","volume":"122","author":"S Bangalore","year":"2009","unstructured":"Bangalore S, Parkar S, Messerli FH. Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis. Am J Med. 2009;122(4):356\u201365. https:\/\/doi.org\/10.1016\/j.amjmed.2008.09.043.","journal-title":"Am J Med"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-020-1262-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-020-1262-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-020-1262-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:27:31Z","timestamp":1611793651000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-020-1262-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,29]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1262"],"URL":"https:\/\/doi.org\/10.1007\/s11886-020-1262-1","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,29]]},"assertion":[{"value":"29 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Jose B. Cruz Rodriguez and Haider Alkhateeb declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"12"}}